Summary Biocartis Group NV (Biocartis) operates as a molecular diagnostics company that provides personalized medicine for patients through its molecular diagnostics.The company undertakes the development of diagnostics technology platforms for multiplexed detection of bio-analytes, with oncology as its key focus area.
Its Idylla is a molecular diagnostics system that provides easy access to clinical molecular diagnostic information.Biocartis also offers a wide range of oncology assays such as Idylla BRAF Mutation Test, Idylla EGFR Mutation Test, Idylla KRAS Mutation Test, and Idylla NRAS Mutation.
The company has operations in Belgium and Switzerland. Biocartis is headquartered in Mechelen, Belgium.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope: - The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments - The report analyzes all pipeline products in development for the company Biocartis Group NV - The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) - The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date - The report provides detailed description of products in development, technical specification and functions - The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy: - Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape - Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio - To formulate effective Research & Development strategies - Develop market-entry and market expansion strategies - Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc - Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Our reports have been used by over 10K customers, including:
Summary Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer.Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi proLung, a validating test...
Summary Sebia SA (Sebia) is a medical device company that designs, manufactures, commercializes, and exports electrophoresis tests and analyzers.The company’s electrophoresis program offers automated system for capillary electrophoresis, gel electrophoresis and electrophoresis scanning software. It also provides...
388 pages •
By Global Industry Analysts
• Apr 2021
- Global Uterine Cancer Therapeutics and Diagnostics Market to Reach $27.7 Billion by 2027
- Amid the COVID-19 crisis, the global market for Uterine Cancer Therapeutics and Diagnostics estimated at US$19.5 Billion in the year 2020, is projected to reach a revised size of US$27.7 Billion by 2027, growing...
Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020
Medical Devices sector report, “Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Colorectal Cancer Diagnostic Tests pipeline products...
Summary Protagen AG (Protagen) is a medical device company that develops molecular diagnostic and companion diagnostic test equipment.The company’s products include multilisa SSC, multilisa SLE and multilisa RA. It provides products for autoimmune diseases such as rheumatoid arthritis, neuromyelitis optica, systemic...
The global cell isolation market size is projected to reach USD 15.0 billion by 2025 from USD 6.9billion in 2020, at a CAGR of 16.8% during the forecast period. Market growth is driven by factors The growing investments in personalized medicine can primarily be attributed to the growing demand for advanced treatments with minimal side-effects...
Gallbladder Cancer - Pipeline Review, H2 2020
latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2020, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.
Gallbladder cancer is a cancer that starts in...
Summary Interpace Biosciences Inc (Interpace Biosciences) formerly Interpace Diagnostics Group Inc, is a developer of molecular diagnostics tests.The company offers PancraGen, a DNA based molecular test that aids in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its pathfinder platform. It...
Summary SomaLogic Inc (SomaLogic) is a life science company that discovers, develops and commercializes life science research tools and clinical diagnostic products.The company’s products include SOMAscan assay and SOMAmer reagents. Its SOMAscan reagents is a proteomic platform that combines the properties of antibodies...
Summary Veracyte Inc (Veracyte) is a molecular diagnostics company that uses genomic technology to resolve diagnostic ambiguity.The company’s pipeline products comprise Afirma thyroid FNA analysis for the diagnosis of thyroid cancer based on its proprietary afirma gene expression classifier. It also provides percepta...
Medical Devices Sales
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.